Ionis Pharmaceuticals (IONS) Cost of Revenue (2018 - 2026)

Ionis Pharmaceuticals' Cost of Revenue history runs 9 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 103.9% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $17.4 million, a 65.55% increase from a year earlier, with the FY2025 full-year figure at $15.9 million, up 41.85% from the prior year.
• Cost of Revenue declined to $3.0 million in Q1 2026 per IONS's latest filing, from $8.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $8.0 million in Q4 2025 and bottomed at $1.1 million in Q3 2024.
• The 5-year median for Cost of Revenue is $3.0 million (2026), against an average of $3.1 million.
• Across the five-year window, Cost of Revenue slumped 67.79% in 2023 and jumped 118.3% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $3.7 million in 2022, then declined by 16.93% to $3.1 million in 2023, then advanced by 25.08% to $3.8 million in 2024, then surged by 107.75% to $8.0 million in 2025, then slumped by 62.51% to $3.0 million in 2026.
• Per Business Quant, the three latest IONS Cost of Revenue figures stand at $3.0 million (Q1 2026), $8.0 million (Q4 2025), and $2.3 million (Q3 2025).